Theriva Biologics will present safety and clinical outcomes from an investigator-sponsored Phase 1 study of intravitreal VCN-01 (zabilugene almadenorepvec) in refractory intraocular retinoblastoma at the APAO Congress in Hong Kong, alongside preclinical data suggesting synergistic activity when combined with topotecan. The Phase 1 protocol evaluated two intravitreal injections in children whose disease had failed systemic, intra-arterial, or intravitreal chemotherapy and for whom enucleation was the recommended option. No new numerical efficacy or safety rates were disclosed ahead of the presentation.
The core development is a potential pivot from monotherapy to a combination strategy designed to improve control of vitreous seeds, a persistent failure mode for standard regimens. By signaling intent to refine a potential pivotal trial design and highlighting existing Orphan Drug and Rare Pediatric Disease designations in retinoblastoma, Theriva is positioning VCN-01 for a streamlined regulatory path if the clinical signal and safety profile are robust. The company’s oncolytic adenovirus has largely been explored systemically in adult solid tumors; here the focus is on localized delivery to preserve the eye in a rare pediatric cancer with limited options once intravitreal chemotherapy fails.
Strategically, the combination with topotecan aligns with prevailing practice patterns while seeking additive benefit from VCN-01’s proposed mechanisms: selective tumor cell lysis, stroma degradation, and immunogenic priming. It is also a pragmatic acknowledgment that monotherapy may not be sufficient against dense vitreous seeding. For sponsors, the appeal is the possibility of a single-arm, eye-salvage focused pivotal in a small population, potentially supported by historical controls if regulators accept endpoints like enucleation-free survival, vitreous seed clearance, and sustained ocular salvage at 12 months. The Rare Pediatric Disease designation introduces a potential priority review voucher if approval is achieved, which can materially influence development financing and timelines.
Operationally, this program will concentrate activity in a small number of experienced retinoblastoma centers capable of intravitreal viral administration under stringent aseptic technique, with specialized imaging and central review to standardize assessments of seed regression. Trials will need virology monitoring for ocular and systemic viral shedding, carefully choreographed dosing with topotecan, and contingency plans for inflammation, uveitis, or endophthalmitis. Immunogenicity may constrain repeat dosing, so durability after two injections will be a pivotal question. CROs and vendors should expect complex logistics: sterile product handling and cold chain to procedure rooms, masked image adjudication, and pediatric-specific safety oversight. Enrollment remains the gating factor; global site networks and harmonized protocols will be essential to reach sample sizes that support regulatory-grade evidence.
Regulators will scrutinize the balance between ocular salvage and safety, particularly the incidence and management of intraocular inflammation and infection, as well as any systemic exposure in a pediatric population. Endpoint selection and statistical plans must accommodate small n while satisfying expectations for clinically meaningful benefit over existing intravitreal chemotherapy. Manufacturing consistency and sterility assurance for a replicating adenovirus administered intravitreally will sit high on CMC risk registers.
What to watch next are the actual numbers from the APAO presentation: ocular salvage rates, seed clearance kinetics, time to enucleation, and the adverse event profile relative to intravitreal chemotherapy alone. Clarity on durability after the two-dose regimen will shape whether the pivotal design centers on combination therapy and how many injections are feasible. Signals of cross-regional regulatory alignment, site expansion beyond a single expert center, and CMC readiness will indicate whether a 2026–2027 pivotal start is realistic. In a rare disease marked by geographic disparities in outcomes, plans for international enrollment and access could determine both feasibility and eventual impact.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
